# Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

> **NCT01016912** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 51 (actual)

## Conditions studied

- Hepatitis C Infection

## Interventions

- **DRUG:** BMS-790052
- **DRUG:** BMS-790052
- **DRUG:** Placebo
- **DRUG:** Peginterferon alfa-2b
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01016912
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01016912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01016912, "Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01016912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*